Akela reports net gain of $1.

December 31 Consolidated net income for the three and twelve months ended, 2010 were $1.5 million, $0.05 per share, and $1.2 million, $0.04 per talk about, versus losses of $14.1 million, per talk about, and losses of $21.0 million, per talk about, for the same respective intervals in 2009 2009. Excluding one time gains and losses, Akela’s consolidated net income for the three and a year ended December 31, 2010 had been $0.8 million, and $0.5 million, pitched against a net loss of $2.2 million, and a net loss of $8.4 million.. Akela reports net gain of $1.5 million for three months ended December 31, 2010 Akela Pharma, Inc. , a head in the advancement of therapeutics for the treating pain, and the business’s wholly owned subsidiary, PharmaForm, today announced its economic results for the three months and 12 months ended December 31, 2010.Assuming equal efficacy of both study remedies, we determined that 88 events would give a power of 90 percent to show that rivaroxaban was noninferior to regular therapy, using a margin of 2.0 for the upper limit of the 95 percent confidence interval for the observed hazard ratio, with a two-sided alpha level of 0.05. The process specified that the steering committee would quit enrollment when it had been estimated that 88 events would be reached. This decision was produced without knowledge of the outcomes in the two study groupings. When enrollment was discontinued, patients completed their assigned treatment except for those in the 12-month stratum who completed at least six months of treatment.